Clinical Trials
-
Principal Investigator:
Aya Haggiagi, MDThe purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI (an FDA-approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA-approved for use in this country. The study drug encorafenib is approved in this country and is... -
Principal Investigator:
Aya Haggiagi, MDThe purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI (an FDA-approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA-approved for use in this country. The study drug encorafenib is approved in this country and is... -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study... -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study... -
Principal Investigator:
Andrew B. Lassman, MDThe purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called "study drugs" and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. -
Principal Investigator:
Andrew B. Lassman, MDThe purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called "study drugs" and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. -
Principal Investigator:
Thomas H. Brannagan III, MDThe purpose of this research is to see if an experimental drug called REGN7544 is effective to treat individuals with postural orthostatic tachycardia syndrome (POTS). REGN7544 is an antibody. An antibody is a kind of protein that your immune (defense) system normally makes to fight bacteria and viruses in your body. Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases. REGN7544 is designed to bind to a cell protein called natriuretic peptide receptor 1 (NPR1), which is found on the surface of different types of cells in the body... -
Principal Investigator:
Giuseppe Tosto, MD, PhDThis study aims to find genes that cause Alzheimer's Disease in African Americans and Hispanics/Latinos. Participants are eligible if African American or Hispanic/Latino and 60 years of age or older. Study participation would entail completing a memory assessment, having their blood drawn, and a brief physical exam with a questionnaire. Compensation of $50 will be provided, if unable to come to Columbia University Irving Medical Center, home visits are available. Participants can live anywhere in the US. -
Principal Investigator:
Philip L. De Jager, MD, PHDThe purpose of this study is to establish a collection of biological fluids and associated data from healthy individuals to determine how genetic and environmental variation affects the immune system. Study visits consist of taking vitals and collecting biological fluids, such as blood. You will be compensated for participating in this study. -
Principal Investigator:
Dritan Agalliu, PhDThe aim of this study is to understand the mechanisms of secondary effects of traumatic brain injury on the blood-brain barrier and to understand the biochemical differences in the blood of people with Alzheimer's disease and the volunteer group. We will compare biochemical blood differences between a healthy group and traumatic brain injury patients and Alzheimer's disease. Our aim is to identify biochemical changes in the blood that may worsen the prognosis in traumatic brain injury and Alzheimer's disease. We are looking for healthy volunteers in certain age groups (18-30, 35-55, 60-80)...